Please ensure Javascript is enabled for purposes of website accessibility

Why AC Immune Stock Surged Today

By Joe Tenebruso - Updated Feb 11, 2021 at 8:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Researchers are excited about the potential of the biotech's investigational Alzheimer's vaccine.

What happened

Shares of AC Immune (ACIU 0.96%) jumped 15% on Thursday after the Swiss-based biopharmaceutical company released promising data from its early-stage study of ACI-35.030, an experimental vaccine for the treatment of Alzheimer's disease (AD). 

So what 

AC Immune's vaccine candidate elicited a "potent" antibody response against pTau -- a protein that scientists believe plays a part in Alzheimer's disease -- in all 32 patients in its Phase 1b/2a clinical trial. "These remarkable data show that ACI-35.030 is capable of generating unprecedented antibody responses against pTau in an elderly population," AC Immune CEO Andrea Pfeifer said in a press release.

A person is pointing to an upwardly sloping line.

AC Immune's stock price rose sharply on Thursday. Image source: Getty Images.

AC Immune believes the antibodies could help to slow the spread of the pTau protein in the brain. In turn, Pfeifer posits ACI-35.030 could potentially serve as "an early intervention for AD, especially when combined with cutting-edge pTau diagnostics that would enable identification of people at risk of developing Tau-driven disease."

Moreover, ACI-35.030 was found to be safe and generally well tolerated, with no adverse events reported.

Now what 

AC Immune said these results support its plans to advance ACI-35.030 into Phase 2/3 clinical trials. The biotech is developing the vaccine candidate in partnership with Janssen Pharmaceuticals, a subsidiary of healthcare giant Johnson & Johnson.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AC Immune SA Stock Quote
AC Immune SA
$3.15 (0.96%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.